Calendario›CRBP›CRB-701 · TEMPO-1

CRB-701 · TEMPO-1

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

Ensayo de Corbus Pharmaceuticals Holdings, Inc. en Carcinoma orofaringeo (OPC).

Fase

Fase 3

Estado

Aún sin reclutar

Participantes

260

previstos

Centros

29

Fin del objetivo primario

dic 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, simple ciego. Comenzó en sep 2026.

Qué mide

Tasa de respuesta objetiva (%) (hasta 24 meses)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum based chemotherapy or immunotherapy (using a check-point inhibitor) It will also learn about the safety of the drug and measure quality of life. The main questions it asks are: * What proportion of participants respond to CRB-701 measured using scans (CT or MRI) * What medical problems do participants experience when taking CRB-701. Researchers will compare CRB-701 with standard of care medicines (drugs that are normally used this disease). Participants will: * Attend clinic every three weeks to receive infusions of CRB-701 or standard of care medicines until the cancer cannot be measured or is not controlled by the treatment they are receiving. * Have a CT or MRI every 6 weeks to measure the effect on their cancer * Complete questionnaires to assess their health status.

Más ensayos de CRBP

Todos los de CRBP, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07768189), actualizada en ago 2026.